Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc. (Nasdaq: ESLA) is a clinical-stage biopharmaceutical company that entered the public markets through a SPAC business combination and operates in the healthcare and immunology sector. The company filed a Form 10-Q with the Securities and Exchange Commission on May 18, 2023, covering its quarterly financial results and disclosures as a reporting public entity. Estrella is focused on developing novel immunotherapeutic candidates, reflecting a broader wave of clinical-stage biotechnology targets that reached public markets via SPAC mergers in recent years. The filing underscores the company's ongoing SEC reporting obligations following its de-SPAC transition. For complete deal history, filing analytics, and real-time data on ESLA and the full SPAC universe, sign up at SpacDesk.